PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 324.00
Bid: 322.00
Ask: 325.00
Change: -13.00 (-3.86%)
Spread: 3.00 (0.932%)
Open: 321.00
High: 326.00
Low: 311.00
Prev. Close: 337.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

13 May 2011 08:25

RNS Number : 5467G
Hutchison China Meditech Limited
13 May 2011
 



 

For filings with the FSA include the annex

For filings with issuer exclude the annex

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i

 

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

HUTCHISON CHINA MEDITECH LTD

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

 

3. Full name of person(s) subject to the notification obligation: iii

 

 Slater Investments Ltd

 

4. Full name of shareholder(s)

(if different from 3.): iv

 

5. Date of the transaction and date on which the threshold is crossed or reached: v

12th May 2011

6. Date on which issuer notified:

12th May 2011

7. Threshold(s) that is/are crossed or reached: vi, vii

Above 6%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

 

Class/type of shares

if possible usingthe ISIN CODE

 

Situation previousto the triggeringtransaction

 

 

Resulting situation after the triggering transaction

 

Numberof Shares

 

NumberofVotingRights

 

Numberof shares

 

Number of votingrights

 

 

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

B11Y2X4

2,710,229

2,710,229

3,585,000

785,000

2,800,000

1.52%

5.41%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate xiii

 

Exercise/ ConversionPeriod xiv

 

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

 

% of votingrights

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Exerciseprice

 

Expirationdate xvii

 

Exercise/Conversionperiod xviii

 

Number of votingrights instrumentrefers to

 

% of voting rights xix, xx

 

Nominal

Delta

 

 

Total (A+B+C)

 

Number of voting rights

Percentage of voting rights

3,585,000

6.93%

 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

 

13. Additional information:

14. Contact name:

 Ralph Baber

15. Contact telephone number:

 + 44 20 7220 9460

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUOUBRASAVARR
Date   Source Headline
17th May 20243:00 pmRNSRetirement of Chairman and new Chairman appointed
17th May 20247:00 amRNSHUTCHMED Data to be Presented at EHA2024 Congress
14th May 20247:00 amRNSHUTCHMED Initiates Registrational Phase III Trial
14th May 20247:00 amRNSHUTCHMED Initiates Phase II/III Trial with Hengrui
10th May 20241:00 pmRNSResult of AGM
8th May 20249:30 amRNSDirectorate Change
26th Apr 20241:30 pmRNSPositive CHMP Opinion for Fruquintinib
22nd Apr 20249:30 amRNSVesting of Awards Under the LTIP
8th Apr 20249:30 amRNS2023 Annual Report and Notice of AGM
5th Apr 20249:30 amRNSData to be Presented at AACR Congress 2024
2nd Apr 20247:00 amRNSHUTCHMED and Innovent Announce NDA Acceptance
28th Mar 20247:00 amRNSSavolitinib sNDA Accepted in China
22nd Mar 20247:00 amRNSInitiation of Registration Stage of P2/3 Trial
14th Mar 20249:00 amRNSLTIP and Share Option Scheme
5th Mar 20248:30 amRNSVesting of awards under the LTIP
28th Feb 202412:45 pmRNSPublication of Form 20-F
28th Feb 202411:30 amRNS2023 Full Year Results and Business Updates
7th Feb 20247:00 amRNSPresentation of Phase III Data on Fruquintinib
2nd Feb 20248:37 amRNSInmagene Exercises Option for Two Drug Candidates
1st Feb 20248:30 amRNSHUTCHMED to Announce 2023 Final Results
30th Jan 20247:12 amRNSHUTCHMED Receives Marketing Approval in Hong Kong
11th Jan 20247:00 amRNSSovleplenib NDA Granted Priority Review in China
29th Dec 20238:30 amRNSTotal Voting Rights
29th Dec 20238:30 amRNSBlocklisting Six Monthly Return
21st Dec 202310:00 amRNSOverseas Regulatory Announcement
13th Dec 20237:00 amRNSInclusion in National Reimbursement Drug List
13th Dec 20237:00 amRNSCompleted Enrollment of Phase II/III Trial
7th Dec 202310:04 amRNSOverseas Regulatory Announcement
1st Dec 20237:00 amRNSClinical Data to be Presented at Congresses
30th Nov 20238:30 amRNSTotal Voting Rights
9th Nov 20237:00 amRNSU.S. FDA Approval of FRUZAQLAâ„¢ (fruquintinib)
24th Oct 20239:30 amRNSVesting of awards under the LTIP
16th Oct 20239:30 amRNSClinical Data to be Presented at ESMO 2023
29th Sep 20239:30 amRNSNDA Submission for Fruquintinib in Japan
29th Sep 20239:30 amRNSTotal Voting Rights
14th Sep 20239:30 amRNSDirector’s Share Dealing
12th Sep 20239:30 amRNSPhase IIIb Savolitinib Results at WCLC 2023
12th Sep 20237:00 amRNSPatient Enrollment Completed for Bridging Study
31st Aug 20239:30 amRNSTotal Voting Rights
29th Aug 20237:00 amRNSBTD in China for Savolitinib for Gastric Cancer
21st Aug 20237:00 amRNSSovleplenib Phase 3 Study Meets Primary Endpoint
7th Aug 20239:30 amRNSExercise of Share Options by a Director
31st Jul 202312:00 pmRNSInterim Results and Business Updates
20th Jul 20237:00 amRNSBreakthrough Therapy Designation for Fruquintinib
13th Jul 20239:30 amRNSChanges to Board and Technical Committee
10th Jul 20237:00 amRNSPhase 1 Study of HMPL-415 Initiated
29th Jun 20239:30 amRNSBlocklisting Six Monthly Return
26th Jun 20239:30 amRNSHUTCHMED to Announce 2023 Half-Year Results
16th Jun 20237:00 amRNSPhase III FRESCO-2 Results in The Lancet
15th Jun 20233:39 pmRNSMAA of Fruquintinib Validated by the EMA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.